<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2385">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130112</url>
  </required_header>
  <id_info>
    <org_study_id>C107177</org_study_id>
    <nct_id>NCT05130112</nct_id>
  </id_info>
  <brief_title>Impact of Airways Function After HFNC Evaluated by IOS</brief_title>
  <official_title>Impact of Airways Function After Short-term Use of High-flow Nasal Cannula Gas Therapy Evaluated by Impulse Oscillometry Systems in Stable Chronic Obstructive Pulmonary Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu Jen Catholic University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fu Jen Catholic University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In addition to pharmacological treatment, nonpharmacological treatment with high-flow nasal&#xD;
      cannula (HFNC) may play a vital role in the treatment of patients with chronic obstructive&#xD;
      pulmonary disease (COPD). The impulse oscillation system (IOS) is new noninvasive technique&#xD;
      to measure the impedance of different portions of the airway with higher sensitivity than&#xD;
      that of the conventional pulmonary function test (PFT). However, whether IOS is an&#xD;
      appropriate technique to evaluate the efficacy of HFNC in improving the impedance of&#xD;
      peripheral small airways in patients with COPD is unclear.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with stable COPD from the chest medicine outpatient department will be&#xD;
      randomized into two groups receiving HFNC or nasal cannula (NC) for 10 min followed by a&#xD;
      4-week washout period and crossover alternatively. We used a novel analytical measurement&#xD;
      technique, IOS, to detect the difference in airway impedance in the participants after the&#xD;
      HFNC or NC interventions. All data, namely IOS parameters, transcutaneous partial pressure of&#xD;
      carbon dioxide, peripheral oxygen saturation, body temperature, respiratory rate, pulse rate,&#xD;
      blood pressure, and PFT results at the time of pre-HFNC, post-HFNC, pre-NC, and post-NC, were&#xD;
      analysed using SPSS (version 25.0, IBM, Armonk, NY, USA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Actual">September 9, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R5</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of R5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>R5%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of R5%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>R20</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of R20</description>
  </primary_outcome>
  <primary_outcome>
    <measure>R20%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of R20%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of R5-20</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>R5-20</description>
  </primary_outcome>
  <primary_outcome>
    <measure>X5-predicted</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of X5-predicted</description>
  </primary_outcome>
  <primary_outcome>
    <measure>X5-predicted%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of X5-predicted%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Fres</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Fres</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Fres%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Fres%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Ax</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Ax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ax%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of Ax%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TcPCO2</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of TcPCO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse rate</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory rate</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>both systolic and diastolic blood pressure</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of both systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of SpO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of FEV1%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of FVC%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of FEV1/FVC%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of FEV3</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>FEV3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV3%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of FEV3%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV3/FVC%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of FEV3/FVC%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMEF</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of MMEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of MMEF%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>MMEF%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of PEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF%</measure>
    <time_frame>immediately after 10 minutes of HFNC or NC</time_frame>
    <description>Changes of PEF%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Small Airway Disorders</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>HFNC then NC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High flow nasal cannula for 10 min (Period 1) and nasal cannula for 10 min (Period 2) after a 4-week washout period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NC then HFNC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal cannula for 10 min (Period 1) and high flow nasal cannula for 10 min (Period 2) after a 4-week washout period</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high flow nasal cannula and nasal cannula</intervention_name>
    <description>HFNC was administered using the MyAIRVO 2 device (Fisher &amp; Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher &amp; Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..&#xD;
NC is administered for 10 min.</description>
    <arm_group_label>HFNC then NC</arm_group_label>
    <arm_group_label>NC then HFNC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age of 20 to 75 years old&#xD;
&#xD;
          -  diagnosis of COPD made by pulmonologist (Kuo YL) if the patient had a long-term&#xD;
             smoking or noxious gas exposure history, typical clinical manifestations, and airflow&#xD;
             limitation with a postbronchodilator FEV1/FVC ratio of &lt; 0.7 in spirometry,4 and&#xD;
&#xD;
          -  provision of written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe and unstable comorbidities or active malignancy&#xD;
&#xD;
          -  history of obstructive sleep apnoea syndrome&#xD;
&#xD;
          -  COPD exacerbation within the 4 weeks prior&#xD;
&#xD;
          -  current use of long-term oxygen therapy or noninvasive ventilation or use within the 6&#xD;
             weeks prior&#xD;
&#xD;
          -  cognitive impairment or a psychiatric disorder&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yen-Liang Kuo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Jen Catholic University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yen-Liang Kuo</name>
      <address>
        <city>New Taipei City</city>
        <zip>24205</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-flow nasal cannula</keyword>
  <keyword>high nasal flow</keyword>
  <keyword>chronic obstructive pulmonary disease (COPD)</keyword>
  <keyword>airway impedance</keyword>
  <keyword>distal airway</keyword>
  <keyword>peripheral airway</keyword>
  <keyword>airway resistance</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

